EXPERIENCE WITH 3 DIFFERENT 3RD-GENERATION CARDIOVERTER-DEFIBRILLATORS IN PATIENTS WITH CORONARY-ARTERY DISEASE OR CARDIOMYOPATHY

被引:14
作者
PORTERFIELD, JG
PORTERFIELD, LM
SMITH, BA
BRAY, L
机构
[1] METHODIST HOSP,MEMPHIS,TN 38104
[2] UNIV TENNESSEE CTR HLTH SCI,MEMPHIS,TN 38163
关键词
D O I
10.1016/0002-9149(93)90676-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical investigations are being performed in multiprogrammable devices whose therapeutic options include antitachycardia pacing, cardioversion, defibrillation and bradycardia pacing. Three different third-generation devices were implanted in 46 research patients at 1 clinical center to document their safety and efficacy for the treatment of malignant ventricular arrhythmias. Additionally, the purpose of the study was to determine if antitachycardia pacing is a desirable and frequently used feature of tiered devices. The Medtronic PCD was implanted in 15 patients (12 men, mean age 60 +/- 13 years, mean ejection fraction 40 +/- 15%), the Ventritex Cadence in 21 patients (17 men, mean age 65 +/- 10 years, mean ejection fraction 38 +/- 12%), and the CPI VENTAK PRx in 10 patients (8 men, mean age 63 +/- 14 years, mean ejection fraction 31 +/- 8%). All patients presented with cardiac arrest or ventricular tachycardia. During follow-up of 10 +/- 6 months (range 1 to 19), 70% of the 20 patients with antitachycardia pacing activated used the feature for spontaneous ventricular tachycardia. The antitachycardia pacing parameters were reprogrammed 20 times in 15 patients. Two thousand six hundred thirty-eight of 2,675 (98%) antitachycardia pacing attempts successfully terminated spontaneous tachyarrhythmias. Low-energy cardioversion or defibrillation terminated tachyarrhythmias in patients where pacing was unsuccessful. One hundred forty-eight episodes of tachycardia were successfully treated directly by shocks in 16 of 46 patients (35%). There were no deaths due to device failure. This initial single-center clinical experience suggests that the PCD, Cadence and VENTAK PRx are all safe and effective tiered therapy devices for the treatment of malignant ventricular arrhythmias. Antitachycardia pacing successfully terminated most episodes of ventricular tachycardia; in patients with this feature activated, it was used frequently but required reprogramming to achieve high levels of success.
引用
收藏
页码:301 / 304
页数:4
相关论文
共 16 条
[1]   CLINICAL-EXPERIENCE, COMPLICATIONS, AND SURVIVAL IN 70 PATIENTS WITH THE AUTOMATIC IMPLANTABLE CARDIOVERTER DEFIBRILLATOR [J].
ECHT, DS ;
ARMSTRONG, K ;
SCHMIDT, P ;
OYER, PE ;
STINSON, EB ;
WINKLE, RA .
CIRCULATION, 1985, 71 (02) :289-296
[2]   EFFICACY OF AUTOMATIC MULTIMODAL DEVICE THERAPY FOR VENTRICULAR TACHYARRHYTHMIAS AS DELIVERED BY A NEW IMPLANTABLE PACING CARDIOVERTER-DEFIBRILLATOR - RESULTS OF A EUROPEAN MULTICENTER STUDY OF 102 IMPLANTS [J].
FROMER, M ;
BRACHMANN, J ;
BLOCK, M ;
SIEBELS, J ;
HOFFMANN, E ;
ALMENDRAL, J ;
OHM, OJ ;
DENDULK, K ;
COUMEL, P ;
CAMM, AJ ;
TOUBOUL, P .
CIRCULATION, 1992, 86 (02) :363-374
[3]   DETERMINANTS OF PACE-TERMINABLE VENTRICULAR-TACHYCARDIA - IMPLICATIONS FOR IMPLANTABLE ANTITACHYCARDIA DEVICES [J].
IP, JH ;
WINTERS, SL ;
SCHWEITZER, P ;
LOTVIN, A ;
TEPPER, D ;
GOMES, AJ .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (11) :1777-1781
[4]   THE AUTOMATIC IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR - EFFICACY, COMPLICATIONS AND SURVIVAL IN PATIENTS WITH MALIGNANT VENTRICULAR ARRHYTHMIAS [J].
KELLY, PA ;
CANNOM, DS ;
GARAN, H ;
MIRABAL, GS ;
HARTHORNE, JW ;
HURVITZ, RJ ;
VLAHAKES, GJ ;
JACOBS, ML ;
ILVENTO, JP ;
BUCKLEY, MJ ;
RUSKIN, JN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (06) :1278-1286
[5]   REDUCTION IN DEFIBRILLATOR SHOCKS WITH AN IMPLANTABLE DEVICE COMBINING ANTITACHYCARDIA PACING AND SHOCK THERAPY [J].
LEITCH, JW ;
GILLIS, AM ;
WYSE, DG ;
YEE, R ;
KLEIN, GJ ;
GUIRAUDON, G ;
SHELDON, RS ;
DUFF, HJ ;
KIESER, TM ;
MITCHELL, LB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (01) :145-151
[6]   IMPROVED PATIENT SURVEILLANCE AND DATA ACQUISITION WITH A 3RD GENERATION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR [J].
LUCERI, RM ;
PUCHFERRAN, RL ;
BROWNSTEIN, SL ;
HABAL, SM ;
DAVID, IB ;
VARDEMAN, LL .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (11) :1870-1874
[7]   CLINICAL-EXPERIENCE IN 77 PATIENTS WITH THE AUTOMATIC IMPLANTABLE CARDIOVERTER DEFIBRILLATOR [J].
MANOLIS, AS ;
TANDEGUZMAN, W ;
LEE, MA ;
RASTEGAR, H ;
HAFFAJEE, CI ;
HUANG, SKS ;
ESTES, NAM .
AMERICAN HEART JOURNAL, 1989, 118 (03) :445-450
[8]   TERMINATION OF MALIGNANT VENTRICULAR ARRHYTHMIAS WITH AN IMPLANTED AUTOMATIC DEFIBRILLATOR IN HUMAN-BEINGS [J].
MIROWSKI, M ;
REID, PR ;
MOWER, MM ;
WATKINS, L ;
GOTT, VL ;
SCHAUBLE, JF ;
LANGER, A ;
HEILMAN, MS ;
KOLENIK, SA ;
FISCHELL, RE ;
WEISFELDT, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (06) :322-324
[9]   CONVERSION RATES OF INDUCED VERSUS SPONTANEOUS VENTRICULAR-TACHYCARDIA BY A 3RD GENERATION CARDIOVERTER DEFIBRILLATOR [J].
PORTERFIELD, JG ;
PORTERFIELD, LM ;
SMITH, BA ;
BRAY, L ;
VOSHAGE, L ;
MARTINEZ, A ;
AKHTAR, M ;
BATSFORD, B ;
CANNON, D ;
FOGOROS, R ;
GUARNIERI, T ;
HAINES, D ;
HERRE, J ;
HIGGINS, S ;
PORTERFIELD, JG ;
PORTERFIELD, LM ;
SMITH, BA ;
BRAY, L ;
VOSHAGE, L ;
MARTINEZ, A ;
HOROWITZ, L ;
IRWIN, J ;
LEVINE, J ;
MALONEY, J ;
MORADY, F ;
MYERBURG, R ;
PORTERFIELD, J ;
PRYSTOWSKY, E ;
VELTRI, E ;
WHARTON, M ;
WINKLE, R ;
ZIMMERMAN, J .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1993, 16 (01) :170-173
[10]   96 EPISODES OF SPONTANEOUS VENTRICULAR-TACHYCARDIA IN 1 WEEK - SUCCESS OF RAMP PACING BY A PACER-CARDIOVERTER-DEFIBRILLATOR [J].
PORTERFIELD, JG ;
PORTERFIELD, LM ;
BRAY, L .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (10) :1440-1443